A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

Part of paid clinical trials in New Haven, Connecticut.

Sponsor
Yale University
Study ID
NCT05838521
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Sacituzumab govitecan — DRUG
    This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132).

Study Details

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.

Key Dates

Start date
Jun 2, 2023
Status verified
Feb 2026
Primary completion
Jun 1, 2026
Completion
Jun 1, 2028

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Sacituzumab Govitecan
    Sacituzumab govitecan, 10 mg/kg for the first 2 weeks of 21-day cycle until progression or adverse effects prohibit further treatment.

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: 4 Years ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Smilow Cancer Hospital at Yale New HavenNew HavenConnecticut06520
Alessandro D. Santin, M.D
[email protected]
203-737-4450
Lisa Baker, R.N
[email protected]
203-785-6398
Cleveland ClinicClevelandOhio44195
Emilie Slanoc, RN
[email protected]
216-318-8858

Find similar trials in New Haven, CT

By condition
Cervical cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Smilow Cancer Hospital at Yale New Haven· New Haven, CTCleveland Clinic· Cleveland, OH

Related Studies